Following a small study, researchers were hopeful that vorinostat, a histone deacetylase inhibitor, and a treatment for cutaneous T-cell lymphoma, would prove beneficial for mesothelioma patients. However, a larger study has found otherwise. Unfortunately, Rolf Stahel, MD, from the University Hospital in Zurich, Switzerland, said another study for a new treatment of mesothelioma, adding bevacizumab (Avastin) to chemotherapy, also yielded disappointing results. Mesothelioma is a rare, fatal cancer resulting from exposure to asbestos. Researchers are determined to find an effective therapy for the deadly disease.
We handle cases across the United States. Allen Stewart is licensed to practice law in Texas, California, New York, Pennsylvania, Missouri, North Carolina, Ohio and Arizona.
Mesothelioma Drug Zolinza Disappoints in Clinical Trials
Contact Us Today